Selected References:
- Actavis Pharma, Inc. Loxapine product labeling. Revised 12/2016. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a6107bb1-3e23-4c5d-bbf4-5e29deff6728&type=display
- Holt RI, Peveler RC. 2011. Antipsychotics and hyperprolcatinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 74(2):141-7.
- Einarson A, Boskovic R. 2009. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 15(3):183-92.
- Maguire GA. 2002. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 63 Suppl 4:56-62.
- Parikh T, et al. 2014. Antipsychotic drugs and safety concerns for breast-feeding infants. South Med J. 2014; 107(11):686-8.
- Torre, DL, and Falorni, A. 2017. Pharmacological causes of hyperprolactinemia. Therapeutics and clinical risk management. 3(5): 929-51.
